| 2023-06 |
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors |
Journal of Clinical Oncology. 2023 Jun;41(16, Suppl.):Meeting Abstract 3148. |
 |
| 2022-10 |
An integrated microfluidic device for automated detection of cancer cells from bile for cholangiocarcinoma prognosis |
MicroTAS 2022 - 26th International Conference on Miniaturized Systems for Chemistry and Life Sciences. 2022 Oct:229-230. |
|
| 2022-07 |
Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S535. |
|
| 2022-07 |
A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S478. |
|
| 2022-06 |
Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma |
Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4120. |
|
| 2022-02-01 |
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma |
Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):550. |
|
| 2022-02 |
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors |
Journal of Clinical Oncology. 2022 Feb;40(4, Suppl.):660. |
|
| 2021-09 |
A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer |
Annals of Oncology. 2021 Sep;32(Suppl. 5):S377. |
|
| 2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma |
Journal of Clinical Oncology. 2021 May;39(15, Suppl.):4143. |
|
| 2021-05 |
A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy |
Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 6025. |
|
| 2020-11 |
An integrated microfluidic platform for cholangiocarcinoma diagnosis from clinical bile juice samples by utilizing multiple affinity reagents |
2020 IEEE 15th International Conference on Nano/Micro Engineered and Molecular System (IEEE Nems 2020). 2020 Nov:261-264. |
|
| 2020-10 |
Psychosocial illness impacts of Taiwanese cancer survivors |
Quality of Life Research. 2020 Oct;29(Suppl. 1):S91. |
|
| 2019-02 |
Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 269. |
|
| 2018-11 |
TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer |
Annals of Oncology. 2018 Nov;29(Suppl. 9):50. |
|
| 2018-10 |
Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P. |
|
| 2018-05 |
A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers |
Journal of Clinical Oncology. 2018 May;36(15, Suppl. S):Meeting Abstract 2556. |
|
| 2017-06 |
A new scoring system for primary central nervous system lymphoma - a retrospective multi-center analysis in Taiwan |
Haematologica. 2017 Jun;102(Suppl. 2):691-692. |
|
| 2017-02 |
A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer |
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):417. |
|
| 2016-02 |
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 134. |
|
| 2016-02 |
Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC) |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 369. |
|
| 2016-02 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 745. |
|
| 2014-01 |
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial |
Journal of Clinical Oncology. 2014 Jan;32(3 Suppl):Abstract number 267. |
|
| 2013-05 |
Impact of virologic factors on recurrence-free survival in HBV-related hepatocellular carcinoma after surgical resection: Post hoc analysis from a prospective study with long-term follow-up |
Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number e15032. |
|
| 2012-09 |
Heat shock protein 90 inhibition downregulates c-Kit expression in gist cells through diminishing transcription and enhancing protein degradation via both autophagy and proteasome pathways |
Annals of Oncology. 2012 Sep;23(Suppl. 9):538. |
|
| 2012-03 |
Involvement of autophagy in endogenous and NVP-AUY922-induced C-kit degradation in both imatinib-sensitive and -resistant gastrointestinal stromal tumor cells |
Annals of Oncology. 2012 Mar;23(Suppl. 1):28. |
|
